Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wundecyte
- Development stage
- Preclinical
- Lead developer
- Tenax Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Wundecyte** is an investigational topical perfluorocarbon oxygen-carrier gel developed by Oxygen Biotherapeutics, now Tenax Therapeutics, for local wound oxygenation. The gel was made from the company's Oxycyte perfluorocarbon platform and was intended to supply oxygen to injured tissue from the outside in, either alone or alongside a separate self-oxygenating bandage. Preclinical work evaluated full-thickness excisional wounds and partial-thickness burns, including wound closure, scar reduction, and infection-control outcomes. ([clpmag.com](https://clpmag.com/miscellaneous/research-contract-signed-to-study-gels-wound-healing-properties/))
- Brand names
- Wundecyte
Beyond the preview
Go deeper on Wundecyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wundecyte.